Central Pharmaceuticals (DHA:CENTRALPHL) LT-Debt-to-Total-Asset: 0.17 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
66 GF Score
Price BDT12.00
GF Value BDT12.06
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Central Pharmaceuticals LT-Debt-to-Total-Asset?

Central Pharmaceuticals DHA:CENTRALPHL +0.84% 66 LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 66/100 and a GF Value™ of BDT12.06 (Fairly Valued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Central Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.17.

Central Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.17). It may suggest that Central Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Central Pharmaceuticals  (DHA:CENTRALPHL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Central Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Central Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Central Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceuticals LT-Debt-to-Total-Asset Chart

Central Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.18 0.18 0.16 0.16

Central Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.16 0.16 0.16 0.17
DHA:CENTRALPHL
66GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Central Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=231.978/1428.954
=0.16

Central Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=231.978/1409.08
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.17 mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a LT-Debt-to-Total-Asset of 0.17 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Central Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.17. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Central Pharmaceuticals' LT-Debt-to-Total-Asset of 0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.06, compared to a current price of BDT12.00 — trading 0.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.17. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current LT-Debt-to-Total-Asset is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT12.00 is trading 0.5% below its estimated GF Value™ of BDT12.06. GuruFocus considers Central Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:CENTRALPHL:

  • LT-Debt-to-Total-Asset: 0.17
  • GF Value™: BDT12.06 vs. price of BDT12.00 (0.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score

Get the complete analysis for DHA:CENTRALPHL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT12.00
Price
BDT12.06
GF Value